Lymphoma Research Foundation announces $10M initiative for follicular lymphoma clinical research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Lymphoma Research Foundation has announced the establishment of the Jaime Peykoff Follicular Lymphoma Initiative, named for follicular lymphoma survivor and wife of Andrew Peykoff II, owner of Niagara Bottling.

Established through the gift of the Peykoff Family and Niagara Cares, the $10 million initiative is designed to convene experts in follicular lymphoma research and patient care, accelerate therapeutic development, and to drive direct investment in clinical research.

LRF assembled a steering committee comprising FL experts to provide thought leadership for the Initiative. This multidisciplinary, multi-institutional panel will ensure all key stakeholders are informed of the initiative’s goals and identify the most significant areas of unmet needs in clinical FL research. The initiative’s steering committee includes the following:

  • Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, Chair

  • Sonali M. Smith, MD, The University of Chicago Medical Center, Vice Chair

  • Stephen Ansell, MD, PhD, Mayo Clinic, Rochester

  • John P. Leonard, MD, Weill Cornell Medicine

  • Brian Link, MD, University of Iowa, Holden Comprehensive Cancer Center

  • Laura Pasqualucci, MD, Columbia University Medical Center

  • John Timmerman, MD, UCLA Jonsson Comprehensive Cancer Center

LRF will develop an international scientific workshop to drive collaboration. Follicular lymphoma thought leaders would share early research findings, discuss the results of pivotal clinical trials, and engage in planning exercises designed to advance FL research.

Under the leadership of the Jaime Peykoff Follicular Lymphoma Initiative Steering Committee and the LRF SAB, LRF will fund both Clinical Investigator Career Development Awards and Senior Investigator Grants to attract senior and early-career investigators and train them in the field of FL research.

For more information about the Jaime Peykoff Follicular Lymphoma Initiative or additional LRF research programs, visit www.lymphoma.org/research.

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login